← Newron Pharmaceuticals S.p.A. (NWRN.SW) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Newron Pharmaceuticals S.p.A. (NWRN.SW)
Pharmaceutical Preparations · market cap $251M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-03-31 (est.)
Phase 3
Pipeline
10
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Newron Pharmaceuticals S.p.A. (NWRN.SW) is a Milan-based specialty pharma with 27 employees and a ~$289M market cap, built around two clinical platforms: safinamide (a marketed add-on therapy for Parkinson's disease with ongoing Phase 3 work) and evenamide (a late-stage candidate for treatment-resistant schizophrenia). The near-term binary is an estimated end-2026 Phase 3 readout for evenamide 15 mg bid in treatment-resistant schizophrenia, rated by the facts as a high-importance catalyst.
The catalyst path
- 2027-03-31 (est.)Phase 3 · Evenamide 15 mg bidimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Safinamide (as add-on therapy) | Phase 3 | Idiopathic Parkinson's Disease |
| Safinimide 50-100 mg/day | Phase 3 | Idiopathic Parkinson's Disease |
| NW-3509A | Phase 2 | Chronic Schizophrenia |
| sNN0029 | Phase 2 | Amyotrophic Lateral Sclerosis |
| Evenamide 15 mg bid | Phase 3 | Treatment-resistant Schizophrenia |
| Ralfinamide | Phase 3 | Pain |
| Safinamide | Phase 3 | Idiopathic Parkinson's Disease |
| sNN0031 | Phase 2 | Parkinson's Disease |
| Evenamide | Phase 2 | Schizophrenia |
| Safinamide + Levodopa | Phase 2 | Idiopathic Parkinson's Disease |
Price & technical context
3-month
-35.9%
6-month
-48.3%
12-month
-39.5%
52-wk range
$7.62–$30.40
vs 50-day MA
-31.8%
vs 200-day MA
-49.6%
Realized vol
62.0%
Max drawdown
-74.9%
Daily closes through 2026-10-06. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NWRN.SW (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.